title: Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
abstract: Anti-clinically amyopathic dermatomyositis (CADM)-140/MDA5 autoantibodies are specifically detected in patients with dermatomyositis and are known to have a strong association with rapidly progressive interstitial lung disease (RP-ILD). Here we report an amyopathic dermatomyositis (ADM) patient who developed RP-ILD characterized by elevated anti-CADM-140/MDA5 titer. Respiratory symptoms gradually improved, and anti-CADM-140/MDA5 titer decreased in parallel to below the cutoff level. It may be useful to quantify CADM-140-specific autoantibodies for monitoring disease activity in patients with ADM and RP-ILD.
authors: Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan. shinsjam@tokai-u.jp
authors: Shinji
authors: S
authors: Sato
authors: Masataka
authors: M
authors: Kuwana
authors: Takashi
authors: T
authors: Fujita
authors: Yasuo
authors: Y
authors: Suzuki
mesh_terms: D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D003882:Dermatomyositis / Q000150:complications / Q000276:immunology / Q000473:pathology*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000276:immunology / Q000473:pathology*; D008875:Middle Aged; D010455:Peptides / Q000097:blood* / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; C501597:CADM-140 peptide, human; D003879:Dermatologic Agents; D005938:Glucocorticoids; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D016572:Cyclosporine; D011239:Prednisolone